United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f), olodaterol hydrochloride (unii: 65r445w3v9) (olodaterol - unii:vd2ysn1afd) - tiotropium 3.124 ug - stiolto respimat is a combination of tiotropium and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use - stiolto respimat is not indicated to treat acute deteriorations of copd [see warnings and precautions (5.2)]. - stiolto respimat is not indicated to treat asthma. the safety and effectiveness of stiolto respimat in asthma have not been established. use of a laba, including stiolto respimat, without an inhaled corticosteroid is contraindicated in patients with asthma [see warnings and precautions (5.1)] . stiolto respimat is not indicated for the treatment of asthma. stiolto respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product [see warnings and precautions (5.4)] . in clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, inc

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium bromide - unii:j697uz2a9j) - ipratropium bromide 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. atrovent hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to ipratropium bromide or other atrovent hfa inhalation aerosol components. atrovent hfa inhalation aerosol is also contraindicated in patients who are hypersensitive to atropine or its derivatives. atrovent® hfa (ipratropium bromide hfa) inhalation aerosol read complete instructions carefully before using. important points to remember about using atrovent hfa inhalation aerosol    although atrovent hfa inhalation aerosol may taste and feel different    when breathed in compared to your atrovent® (ipratropium    bromide) inhalation aerosol cfc inhaler, they contain the same    medicine.    you do not have to shake the atrovent hfa inhalation aerosol canister    before using it.    atrovent hfa inhala

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - tiotropium bromide monohydrate 18 ug - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to ipratropium or tiotropium.  in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. teratogenic effects, pregnancy category c. there are no adequate and well-controlled studies in pregnant women.  spiriva handihaler should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. no evidence of structural alterations was observed in rats and rabbits at inhalation tiotropium doses of up to approximately 660 and 6

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - tiotropium 18 ug - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was

United States - English - NLM (National Library of Medicine)

ritedose pharmaceuticals, llc - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - albuterol 2.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. atrovent hfa is contraindicated in the following conditions [see warnings and precautions (5.2) ]. - hypersensitivity to ipratropium bromide or other atrovent hfa components - hypersensitivity to atropine or any of its derivatives risk summary ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . there is limited experience with ipratropium bromide use in pregnant women. published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. based on animal reproduction studies, no evidence of structural alteration

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - ipratropium bromide - nebuliser liquid - 250microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - ipratropium bromide - nebuliser liquid - 250microgram/1ml

United States - English - NLM (National Library of Medicine)

american health packaging - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. ipratropium bromide and albuterol sulfate inhalation solution 0.5 mg / 3 mg per 3 ml patient's instructions for use read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been prescribed. contact them if you have additional question

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.